{"title":"揭示GLP-1受体激动剂药物的广泛健康益处和风险","authors":"","doi":"10.1038/s41591-024-03476-8","DOIUrl":null,"url":null,"abstract":"This study systematically analyzed 175 health outcomes in 2 million people using glucagon-like peptide-1 receptor agonists (GLP-1RAs) or other antihyperglycemics. GLP-1RAs reduce risks of neurocognitive, substance use, cardiovascular and respiratory disorders, but increase risks of gastrointestinal issues, hypotension and pancreatitis. The study provides important insights for clinical practice and future research.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"15 1","pages":""},"PeriodicalIF":58.7000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unlocking the broad health benefits and risks of GLP-1 receptor agonist drugs\",\"authors\":\"\",\"doi\":\"10.1038/s41591-024-03476-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This study systematically analyzed 175 health outcomes in 2 million people using glucagon-like peptide-1 receptor agonists (GLP-1RAs) or other antihyperglycemics. GLP-1RAs reduce risks of neurocognitive, substance use, cardiovascular and respiratory disorders, but increase risks of gastrointestinal issues, hypotension and pancreatitis. The study provides important insights for clinical practice and future research.\",\"PeriodicalId\":19037,\"journal\":{\"name\":\"Nature Medicine\",\"volume\":\"15 1\",\"pages\":\"\"},\"PeriodicalIF\":58.7000,\"publicationDate\":\"2025-01-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41591-024-03476-8\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-024-03476-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Unlocking the broad health benefits and risks of GLP-1 receptor agonist drugs
This study systematically analyzed 175 health outcomes in 2 million people using glucagon-like peptide-1 receptor agonists (GLP-1RAs) or other antihyperglycemics. GLP-1RAs reduce risks of neurocognitive, substance use, cardiovascular and respiratory disorders, but increase risks of gastrointestinal issues, hypotension and pancreatitis. The study provides important insights for clinical practice and future research.
期刊介绍：
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
